4,136 Shares in Labcorp Holdings Inc. $LH Bought by Lombard Odier Asset Management Switzerland SA

Lombard Odier Asset Management Switzerland SA purchased a new stake in shares of Labcorp Holdings Inc. (NYSE:LH) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 4,136 shares of the medical research company’s stock, valued at approximately $1,104,000.

A number of other hedge funds have also recently modified their holdings of the company. JPL Wealth Management LLC bought a new position in shares of Labcorp during the third quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Labcorp during the 4th quarter valued at about $26,000. Hilton Head Capital Partners LLC bought a new position in Labcorp during the 4th quarter valued at approximately $27,000. Eagle Bay Advisors LLC bought a new position in Labcorp during the 4th quarter valued at approximately $29,000. Finally, DV Equities LLC purchased a new stake in Labcorp in the 4th quarter worth approximately $29,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Insider Buying and Selling

In related news, EVP Kathryn W. Kyle sold 762 shares of Labcorp stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $263.89, for a total transaction of $201,084.18. Following the completion of the transaction, the executive vice president directly owned 3,813 shares of the company’s stock, valued at $1,006,212.57. This trade represents a 16.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan T. Vaughn sold 234 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $66,968.46. Following the sale, the executive vice president directly owned 6,746 shares in the company, valued at $1,930,637.74. The trade was a 3.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 6,991 shares of company stock worth $1,796,696 in the last three months. 0.84% of the stock is owned by corporate insiders.

Labcorp Trading Up 1.4%

NYSE LH opened at $301.03 on Tuesday. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. Labcorp Holdings Inc. has a twelve month low of $244.52 and a twelve month high of $301.79. The firm has a market capitalization of $24.68 billion, a PE ratio of 26.66, a P/E/G ratio of 1.97 and a beta of 0.89. The stock’s 50 day moving average is $270.30 and its 200 day moving average is $269.49.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $4.09 by $0.16. The company had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Research analysts forecast that Labcorp Holdings Inc. will post 18 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 28th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Friday, August 28th. Labcorp’s dividend payout ratio (DPR) is presently 25.51%.

Analyst Ratings Changes

A number of analysts recently commented on LH shares. Weiss Ratings raised Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday. Evercore reissued an “outperform” rating and set a $300.00 price objective on shares of Labcorp in a research report on Wednesday, April 8th. Robert W. Baird upped their price objective on shares of Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Bank of America raised their target price on shares of Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $315.33.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.